Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance

Summary

The protocol presents a noninvasive method for the rapid diagnosis of Helicobacter pylori stomach infections through the string test and determines its antibiotic resistance to clarithromycin and levofloxacin using quantitative polymerase chain reaction (qPCR).

Abstract

Helicobacter pylori is a major human pathogen that infects approximately half of the global population and is becoming a serious health threat due to its increasing antibiotic resistance. It is the causative agent of chronic active gastritis, peptic ulcer disease, and gastric cancer and has been classified as a Group I Carcinogen by the International Agency for Research on Cancer. Therefore, the rapid and accurate diagnosis of H. pylori and the determination of its antibiotic resistance are important for the efficient eradication of this bacterial pathogen. Currently, H. pylori diagnosis methods mainly include the urea breath test (UBT), the antigen test, the serum antibody test, gastroscopy, the rapid urease test (RUT), and bacterial culture. Among them, the first three detection methods are noninvasive, meaning they are easy tests to conduct. However, bacteria cannot be retrieved through these techniques; thus, drug resistance testing cannot be performed. The last three are invasive examinations, but they are costly, require high skills, and have the potential to cause damage to patients. Therefore, a noninvasive, rapid, and simultaneous method for H. pylori detection and drug resistance testing is very important for efficiently eradicating H. pylori in clinical practice. This protocol aims to present a specific procedure involving the string test in combination with quantitative polymerase chain reaction (qPCR) for the rapid detection of H. pylori infection and antibiotic resistance. Unlike bacterial cultures, this method allows for easy, rapid, noninvasive diagnosis of H. pylori infection status and drug resistance. Specifically, we used qPCR to detect rea for H. pylori infection and mutations in the 23S rRNA and gyrA genes, which encode resistance against clarithromycin and levofloxacin, respectively. Compared to routinely used culturing techniques, this protocol provides a noninvasive, low-cost, and time-saving technique to detect H. pylori infection and determine its antibiotic resistance using qPCR.

Introduction

H. pylori is a spiral-shaped, highly motile, gram-negative bacterium that mainly lives in the pylorus region of the stomach¹. It is a common pathogen that infects nearly 50% of the global population². Most people with H. pylori infection have no clinical manifestations, and most develop different diseases after several years of infection, including chronic gastritis, peptic ulcers, gastric ulcers, and gastric cancer³. In several studies based on different populations, the efficacy of eliminating H. pylori for preventing stomach cancer and precancerous lesions has been demonstrated^4,5. Therefore, the World Health Organization (WHO) International Agency for Research on Cancer has advised H. pylori eradication as a preventative measure⁶.

The use of noninvasive methods to identify H. pylori infection is a key component of treatment for most individuals with asymptomatic dyspepsia. The urea breath test (UBT), H. pylori fecal antigen test (SAT), and serological testing are popular noninvasive techniques. Among these, the UBT is the least intrusive and most accurate procedure available. UBT uses urease, abundantly present in H. pylori, to hydrolyze isotopically labeled urea into ammonia and carbon dioxide (13C or 14C). In contrast, the immunochromatographic assay (ICA)⁷ is convenient, simple, and noninvasive for sampling. However, the accuracy of the test is affected by several factors, such as the quality of the stool sample, the temperature, and the interval between the sample collection and testing. Another test based on the immune response is the serum H. pylori antibody test, which detects antibodies in a patient's serum. However, this test is not suitable for post-treatment analysis since the antibodies remain long after the bacteria have been cleared⁸. Another major drawback is that these methods only diagnose H. pylori infection and do not allow for drug resistance testing to guide sensitivity-based treatment.

For invasive testing methods, gastric biopsy tissue needs to be taken by endoscopy and then subjected to histology, the urease rapid test, and bacterial culture. These testing methods are also very limited due to several factors. Currently, these techniques are limited to elderly patients, patients at high risk for precancerous or malignant disease, and patients who have failed first-line therapy for gastroesophageal reflux disease or H. pylori infection⁹. Secondly, due to the unique growth characteristics of H. pylori, the success rate of bacterial culture only reaches 50%¹⁰. Thus, molecular detection methods offer new hope to overcome the high demands of invasive detection methods and guide sensitivity-based treatment. Among molecular detection methods, quantitative PCR has evolved tremendously in recent years. qPCR, unlike traditional PCR, does not require gel electrophoresis and accurately quantifies DNA/RNA in samples by adding primers and probes at the annealing stage. qPCR kits for the detection of H. pylori infection and drug resistance are now commercially available. Nevertheless, each method has its limitations; therefore, a patient's clinical diagnosis and treatment should be considered in conjunction with their symptoms, signs, history, other laboratory tests, and response to treatment.

Currently, the primary method of treating H.pylori infections is taking antibiotics, but lately, it is becoming increasingly difficult to treat these infections due to the rise in antibiotic resistance. Subsequently, a significant decline in H. pylori treatment efficacy has been observed globally, making H. pylori eradication a major public health issue¹¹.

Clarithromycin and levofloxacin are the two broad-spectrum antibiotics used to treat infections caused by H.pylori, but several studies have reported widespread resistance against these two drugs in H.pylori isolates. A2143G, A2142G, and A2142C are three of the numerous point mutations found in the 2.9 kb 23S rRNA gene that result in clarithromycin resistance by preventing the macrolide from binding. At the same time, the mutation loci of the levofloxacin resistance gene are mainly located in the six mutation sites (A260T, C261A, T261G, G271A, G271T, A272G) of the gyrA gene¹². The discovery of these resistance mechanisms based on genetic mutations has led to a gradual shift in the detection of H. pylori through cultural-based studies to molecular testing.

Overall, there is an urgent clinical need for a noninvasive, effective, and simultaneous diagnostic method for the detection of H. pylori infections and drug resistance. We adopted a combined string test and qPCR method to overcome the difficulties of sampling and achieve the goal of the simultaneous detection of H. pylori infection and drug resistance using different primer probes.

Protocol

The present study was conducted in conformity with ethical considerations established by the ethical committee of Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China (Approval Number: KY-Q-2022-384-02). Patients in the age range of 18-60 years old were included in this study. Patients taking antibiotics, antibacterial Chinese medicines, drugs such as proton pump inhibitors (PPI), or H₂ receptor antagonists, etc., within 2 weeks prior to testing were not included in this study. Those patients who had received treatment against H.pylori in the past 3 months were also excluded from this study. Those with serious heart, liver, kidney problems, severe neuropathy, or mental illness were also not allowed to participate in this study. There were no pregnant women and lactating mothers included in this study. Details of the supplies (reagents, chemicals, equipment, and software) used in this study are given in the Table of Materials.

1. String test for gastric fluid sampling

1. Ask the patient to fast overnight before the sample collection.
2. The next day, open the string test kit, take the capsule, and hold the loop at the end of the string.
3. Tape the string onto the patient's cheek, and ask them to place the capsule on their tongue near the back of the throat and swallow it with a sip of water.
4. Allow the capsule to be dissolved in the patient's stomach, thus exposing the string within the capsule to absorb gastric mucus.
5. Ask a trained assistant to pull out the string carefully 1 h after the patient swallowed the capsule.
6. Cut off the lower end of the string (40 cm) soaked in the gastric fluid, place it in the TSE (Tris/saline/EDTA) sample preservation solution, and then send it to the clinical laboratory at room temperature (RT) for the subsequent detection of H. pylori and the determination of the antibiotic resistance profiles using qPCR.

2. DNA extraction

1. Place the specimen-carrying collection tubes on a test tube rack, properly labeled, and vortex them for 10 s.
2. Turn the 32-well plate (nucleic acid extraction or purification kit) upside down several times to resuspend the magnetic beads. After a short vortex for 10 s, carefully remove the aluminum foil sealing from the plate.
3. Transfer 200 µL of gastric fluid from each sample and H. pylori DNA as a positive control into the separate wells.
4. Place the 32-well plate in the corresponding sample slot of the nucleic acid extractor machine for automatic DNA extraction.
5. After DNA extraction and confirmation, initiate the antibiotic resistance testing for clarithromycin and levofloxacin through qPCR on the positive samples.
6. Place the excessive gastric fluid and extracted DNA samples at −20 °C for long-term storage and future use.
7. Perform all these steps in a biosafety cabinet to avoid any contamination.

3. qPCR for the detection of H. pylori and resistance to antibiotics (clarithromycin and levofloxacin)

1. Perform qPCR for the detection of H. pylori and the suspected antibiotic resistance mutations in its genome.
   1. Thaw the qPCR reaction mixture (H. pylori nucleic acid detection kit) on ice, and mix it by flicking and spinning to prevent any loss of reagent.
   2. For each sample on a 32-well plate, mix 20 µL of PCR reaction mixture (genotyping reaction premix [containing the Taq enzyme, deoxyribonucleoside triphosphate, reaction buffer, and magnesium chloride], with ureA forward and reverse primers, and a ureA probe), and 5 µL of the extracted DNA.
   3. Run the 32-well qPCR plate on the qPCR machine. Program the thermal cycler: the reaction mixture will be first reacted sequentially at 42 °C and 95 °C (both for one cycle) for 2 min each; then, 40 cycles at 95 °C, denaturation for 10 s, and annealing and extension at 58 °C for 45 s.
   4. Set the fluorescence signal acquisition to FAM (H. pylori) and the data acquisition to the amplification extension period. After the reaction is completed, save the data for future results analysis.
   5. Analyze the data using specific software for qPCR, as the instrument will automatically select baseline thresholds.
   6. If the test result for H. pylori is positive, the machine will automatically start drug resistance testing on the sample. Replace the reagent kit with detection reagents for 23S rRNA gene and gyrA gene mutations in the H. Pylori (qPCR) kit.
      NOTE: The reagent kit (detection reagents for 23S rRNA gene and gyrA gene mutations in Helicobacter pylori [qPCR]) includes the PCR reaction mixture (genotyping reaction premix [containing the Taq enzyme, deoxyribonucleoside triphosphate, reaction buffer, magnesium chloride], primers, and probes). All the negative quality control products are sterile, purified water. The positive quality control product in the H. pylori nucleic acid detection kit is inactivated H. pylori standard beads (ATCC 43504). The strong H. pylori-positive and weak positive quality control products in the kit (detection reagents for 23S rRNA gene and gyrA gene mutations in H. pylori) are the DNA of the inactivated H. pylori strain containing the target gene and the mutant gene. Similarly, based on the actual situation, all diagnostic standards, including the presence of H. pylori infection or drug resistance, are set to CT ≤ 35 and have a typical S-shaped curve. The concentration of the weak quality control is 1.0 x 10³ copies/mL, while the concentration of the strong quality control is 1.0 x 10⁸ copies/mL.

Results

Detection of H. pylori infection and antibiotic resistance in stomach fluid by qPCR
We performed qPCR for the detection of H. pylori infection by amplifying the ureA gene and determined its antibiotic resistance profile by targeting point mutations in the 23S rRNA gene and gyrA gene (Table 1). The quality control CT values in all three groups of the qPCR experiments were within the recommended range, indicating that the samples were all in a norm...

Discussion

H. pylori detection can be performed using both invasive and noninvasive methods¹³. Commonly used invasive techniques such as histopathology, the rapid urease test, polymerase chain reaction (PCR), and bacterial culturing require endoscopy and biopsy.Serological tests, urea breath tests, and enzyme-linked immunosorbent assays (ELISA) are recommended among the noninvasive procedures¹⁴. While noninvasive methods are easy to perform, economical, and more comfortable f...

Materials

Name	Company	Catalog Number	Comments
23S rRNA and gyrA gene point mutations detection kit (PCR-Fluorescence Probing)	Hongmed Infagen		Detection of Helicobacter pylori resistance to clarithromycin and levofloxacin
ABI 7500 fluorescence quantitative PCR machine	Thermo Fisher Scientific	SEDA 20163220767	Fluorescent quantitative PCR amplification
ABI 7500 software	Thermo Fisher Scientific		Data Analysis
BSC-1500IIA2-X	BIOBASE	SEDA 20143222263	Biosafety cabinet
DNA extraction kit	Daan Gene
E-Centrifuge	WEALTEC		Centrifuge the residual liquid off the wall of the tube.
H. Pylori DNA detection kit (PCR-Fluorescence Probing)	Hongmed Infagen		Testing for H. pylori infection
Stream SP96 automated nucleic acid extractor	Daan Gene	SEDA 20140104	For DNA extraction
String test kit	Hongmed Infagen		It contains a capsule attached to a string, scissors, cotton swab, and sample preservation tube
Ultra-low temperature freezers (DW-YL450)	MELING	SEDA 20172220091	-20 °C for storing reagents
Vortex-5	Kylin-bell		For mixing reagent